Orexo Shares Dip 0.37% on Q3 Losses, Focus on Restructuring & Regulatory ChallengesOrexo shares dip 0.37% after reporting a Q3 loss amid DOJ settlement, yet remain focused on drug‑delivery tech and cost control.OREXO ABSweden Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Jake Connors 23/10/2026, 20:33 2 minutes to read
